
-
Rafael Holdings Inc NEW YORK STOCK EXCHANGE INC.:RFL Rafael Holdings is focused on development of novel cancer therapies. The Company is a significant investor in two clinical stage oncology companies, Rafael Pharmaceuticals, Inc. and LipoMedix Pharmaceuticals Ltd. Through its wholly owned Barer Institute subsidiary, the Company is developing a pipeline of compounds focused on the regulation of cancer metabolism.
Location: | Website: rafaelholdings.com | Industry: | Sector:
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
6.081M
Cash
48.32M
Avg Qtr Burn
-2.124M
Short % of Float
0.50%
Insider Ownership
20.86%
Institutional Own.
9.93%
Qtr Updated
01/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
CPI-613 (devimstat) Details Blood cancer, Cancer, Leukemia, Lymphoma | Failed Discontinued | |
CPI-613 (devimstat) + hydroxychloroquine Details Solid tumor/s, Cancer, Sarcoma | Failed Discontinued | |
CPI-613 (devimstat) Details Blood cancer, Cancer, Acute myeloid leukemia | Failed Discontinued | |
CPI-613 (devimstat) Details Solid tumor/s, Pancreatic cancer, Cancer | Failed Discontinued | |
CPI-613 (devimistat) Details Solid tumor/s, Pancreatic cancer, Cancer | Failed Discontinued |